Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan vs hydrochlorothiazide vs placebo crossover trial in metabolic syndrome
2004-005013-11Phase 2Completed
- Sponsor
- Umeå University Hospital
- Start
- Dec 2004
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of candesartan, hydrochlorothiazide in cardiometabolic risk (CMR), hypertension (HTN), sponsored by Umeå University Hospital. Started Dec 2004; status: completed.
02
Drugs
candesartanhydrochlorothiazide
03
Conditions
cardiometabolic risk (CMR)hypertension (HTN)
Beyond the preview
Go deeper on 2004-005013-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005013-11.